These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22692073)

  • 1. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
    Zhao LP; Xue C; Zhang JW; Hu ZH; Zhao YY; Zhang J; Huang Y; Zhao HY; Zhang L
    Chin J Cancer; 2012 Oct; 31(10):476-83. PubMed ID: 22692073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
    Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
    Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z; Han B; Shen J; Gu A; Zhong H
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
    Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J
    Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhang X; Jin FS; Zhang LG; Chen RX; Zhao JH; Wang YN; Wang EF; Jiang ZD
    Asian Pac J Cancer Prev; 2013; 14(7):4261-5. PubMed ID: 23991987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
    Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
    Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
    Dong X; Hao Y; Wei Y; Yin Q; Du J; Zhao X
    PLoS One; 2014; 9(3):e92320. PubMed ID: 24647522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
    Han QL; Zhou YH; Lyu Y; Yan H; Dai GH
    J Clin Pharm Ther; 2018 Apr; 43(2):163-169. PubMed ID: 29214667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
    Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
    Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
    J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
    PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
    Ma K; Li E; Guo Y; Wang X; Sun H; Shao G
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):505-10. PubMed ID: 25327655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
    Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
    BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.